Man Group
FDMT icon

Man Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Man Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$909K Buy
68,349
+39,366
+136% +$384K ﹤0.01% 1886
2026
Q1 		$270K Buy
28,983
+1,949
+7% +$17K ﹤0.01% 2236
2025
Q4 		$203K Buy
27,034
+8,546
+46% +$86.7K ﹤0.01% 2124
2025
Q3 		$161K Sell
18,488
-116,444
-86% -$696K ﹤0.01% 2130
2025
Q2 		$501K Buy
134,932
+82,980
+160% +$292K ﹤0.01% 1830
2025
Q1 		$168K Buy
+51,952
New +$245K ﹤0.01% 2059
2022
Q4 		– Sell
-48,674
Closed -$391K – 2052
2022
Q3 		$391K Buy
+48,674
New +$441K ﹤0.01% 1591
2022
Q2 		– Hold
0
– – – 1898

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Man Group's FDMT Position: Q2 2026 in Review

Man Group increased its 4D Molecular Therapeutics (FDMT) stake by 136% in Q2 2026, buying an estimated $384K and bringing the position to 68,349 shares worth $909K. The position accounts for ﹤0.01% of the portfolio, ranked #1886.

Man Group first reported a position in FDMT in Q3 2022 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Man Group held 68,349 shares of 4D Molecular Therapeutics worth $909K as of Q2 2026.
  • Man Group bought 39,366 4D Molecular Therapeutics shares in Q2 2026, an estimated $384K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1886 holding.
  • Man Group first reported a position in 4D Molecular Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.